

January 28, 2021

**British Columbia
Securities
Commission**

701 West Georgia
Street
Vancouver, BC
V7Y 1L2

**Alberta
Securities
Commission**

250 5th Street
West
Calgary, AB
T2P 0R4

**Manitoba
Securities
Commission**

500 – 400 St Mary
Avenue
Winnipeg, MB
R3C 4K5

**Ontario
Securities
Commission**

5251 Duke
Street
Halifax, NS
B3J 1P3

**Canadian
Securities
Exchange**

100 King Street
West
Toronto, ON
M5X 1E1

Dear Sirs/Mesdames:

Re: Bright Minds Biosciences Inc. (“the Company”)

We refer to the prospectus of the Company dated January 28, 2021 relating to the distribution of 16,000 common shares of the Company, issuable for no additional consideration upon the deemed exercise of 40,000 special warrants of the Company (at \$0.50 per special warrant).

We consent to being named and to the use, in the above-mentioned prospectus, of our report dated January 28, 2021 to the directors of the Company on the following financial statements:

- Consolidated statements of financial position as at September 30, 2020 and September 30, 2019; and
- Consolidated statements of comprehensive loss, changes in shareholders' equity and cash flows for the year ended September 30, 2020 and the period from incorporation on May 31, 2019 to September 30, 2019.

We report that we have read the prospectus and all information therein and have no reason to believe that there are any misrepresentations in the information contained therein that are derived from the financial statements upon which we have reported or that are within our knowledge as a result of our audit of such financial statements. We have complied with Canadian generally accepted standards for an auditor's consent to the use of a report of the auditor included in an offering document, which does not constitute an audit or review of the prospectus as these terms are described in the CPA Canada Handbook – Assurance.

Yours truly,



CHARTERED PROFESSIONAL ACCOUNTANTS